Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
(NY:
GRDN
)
23.08
+1.01 (+4.58%)
Official Closing Price
Updated: 7:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about GRDN
Aecom Reports Q4 Results, Joins Incyte And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
November 19, 2024
Via
Benzinga
Guardian Pharmacy Services, Inc. Reports Third Quarter 2024 Financial Results
November 12, 2024
From
Guardian Pharmacy Services, Inc.
Via
Business Wire
Earnings Scheduled For November 12, 2024
November 12, 2024
Via
Benzinga
Guardian Pharmacy Services, Inc. to Participate in Upcoming Investor Conference
October 31, 2024
From
Guardian Pharmacy Services, Inc.
Via
Business Wire
Guardian Pharmacy Services, Inc. to Report Third Quarter 2024 Financial Results and Host Conference Call
October 30, 2024
From
Guardian Pharmacy Services, Inc.
Via
Business Wire
Newly Listed Guardian Pharmacy Is Well Positioned In Highly Fragmented Market, Analyst Initiates With Buy Rating
October 21, 2024
Truist initiates coverage of Guardian Pharmacy, projecting a $22 price target due to strong growth in the $24.8 billion institutional pharmacy market.
Via
Benzinga
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
October 21, 2024
Via
Benzinga
Self-Driving Startup Pony.ai Files For U.S. IPO
October 20, 2024
Self-driving startup Pony.ai of China filed for an IPO in the U.S. this week. Meanwhile, four companies -- Springview Holdings, Oriental Rise Holdings, PTL Limited, and Samfine Creation Holdings Group...
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
Obesity Drug Developer BioAge Makes Nasdaq Debut
September 29, 2024
Shares of BioAge Labs opened for trading this week, with the company planning to use the proceeds of its initial public offering to take its lead obesity drug further into clinical trials.
Via
Talk Markets
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.